Menu Search
Equities

MindMaze Therapeutics Holding SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
V6M:STU

MindMaze Therapeutics Holding SA

Actions
  • Price (EUR)1.15
  • Today's Change-0.012 / -1.03%
  • Shares traded0.00
  • 1 Year change--
  • Beta-0.5289
Data delayed at least 15 minutes, as of Feb 16 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

RELIEF THERAPEUTICS Holding SA is a Switzerland-based biopharmaceutical company. The Company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. It specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The Company is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases.

  • Revenue in CHF (TTM)4.05m
  • Net income in CHF-17.04m
  • Incorporated2017
  • Employees31.00
  • Location
    MindMaze Therapeutics Holding SAAvenue de Secheron 15GENEVE 1202SwitzerlandCHE
  • Phone+41 447235959
  • Fax+41 447269012
  • Websitehttps://relieftherapeutics.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		MMTX:SWX since
announced		Transaction
value
NeuroX Group SADeal completed29 Jul 202529 Jul 2025Deal completed-54.89%583.41m
Data delayed at least 15 minutes, as of Feb 16 2026 16:31 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.